Roivant Sciences Ltd. (ROIV): Free Cash Flow
-$758.56M
Year ended 2026-03-31
-$821.06M
Trailing 12 months to 2026-06-30
| Period ended | Free Cash Flow | Change YoY | Source filing |
|---|---|---|---|
| 2026-03-31 | -$758.56M | n/m | 2026-05-20, From 2025-04-01 |
| 2025-03-31 | -$844.05M | n/m | 2026-05-20, From 2024-04-01 |
| 2024-03-31 | -$766.65M | n/m | 2026-05-20, From 2023-04-01 |
| 2023-03-31 | -$856.08M | n/m | 2025-05-29, From 2022-04-01 |
| 2022-03-31 | -$695.16M | n/m | 2023-06-28, From 2021-04-01 |
| 2021-03-31 | -$557.94M | n/a | 2022-06-28, From 2020-04-01 |
Free Cash Flow at similar companies
| Company | Year ended | Free Cash Flow | Change YoY |
|---|---|---|---|
| Roivant Sciences Ltd. (ROIV) | 2026-03-31 | -$758.56M | n/m |
| Aclaris Therapeutics, Inc. (ACRS) | 2025-12-31 | -$47.22M | n/m |
| Bolt Biotherapeutics, Inc. (BOLT) | 2025-12-31 | -$39.92M | n/m |
| Adagene Inc. (ADAG) | 2025-12-31 | -$15.67M | n/m |
| BioAge Labs, Inc. (BIOA) | 2025-12-31 | -$82.35M | n/m |
| Xenon Pharmaceuticals Inc. (XENE) | 2025-12-31 | -$279.92M | n/m |
| International Stem Cell Corp (ISCO) | 2025-12-31 | -$35.0K | n/m |
| Ovid Therapeutics Inc. (OVID) | 2025-12-31 | -$38.33M | n/m |
| Whitehawk Therapeutics, Inc. (WHWK) | 2025-12-31 | -$97.98M | n/m |
Compare ROIV, ACRS, BOLT, ADAG side by side · Screen every company in Pharmaceutical Preparations ↗